SARS-CoV-2 vaccines in development

@article{Krammer2020SARSCoV2VI,
  title={SARS-CoV-2 vaccines in development},
  author={Florian Krammer},
  journal={Nature},
  year={2020},
  pages={1-12}
}
  • F. Krammer
  • Published 23 September 2020
  • Biology
  • Nature
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed… 
View on Springer
nature.com
1,274 Citations
Highly Influential Citations
66
Background Citations
613
Methods Citations
49
Results Citations
8

1,274 Citations

An overview of current COVID-19 vaccine platforms

COVID-19 Vaccines: A Primer for Clinicians.

A summary of the host immune responses to SARS-CoV-2 infection, the vaccine platforms being used with COVID-19 vaccine candidates undergoing, or about to undergo, Phase III clinical trial testing, and an overview of the key criteria necessary for COVID -19 vaccine efficacy and safety are provided.

Correlates of Vaccine-Induced Protection against SARS-CoV-2

Reports are reported on immunogenicity against natural SARS-CoV-2 infection, vaccine-induced immune responses and immunological markers that can be linked to protection and a comprehensive overview of possible efficacy measures and CoP.

Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward

This review analyzes the complexities, challenges, and other vital issues associated with the development of the SARS-CoV-2 vaccine to find the ways to speed up vaccine development.

mRNA Vaccines in the COVID-19 Pandemic and Beyond.

This review gives a detailed overview about the types of mRNA vaccines developed for SARS-CoV-2, discusses and compares preclinical and clinical data, gives a mechanistic overview about immune responses generated by mRNA vaccination, and speculates on the challenges and promising future of this emergent vaccine platform.

Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.

The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against CO VID-19.

Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.

An overview of therapeutic options for COVID-19 as well as vaccines for protection against SARS-CoV-2 is provided.

An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination

This review summarizes the main knowledge that is known about the humoral immune response during COVID-19 disease or after vaccination and should help to optimize vaccination strategies and public health decisions.

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

The different types of vaccines designed and developed against SARS-CoV-2 are reviewed, placing emphasis on whether they are based on the complete S glycoprotein, its antigenic domains such as the receptor-binding domain (RBD) or short epitopes within the S Glycoprotein.
...

References

SHOWING 1-10 OF 95 REFERENCES

Development of an inactivated vaccine candidate for SARS-CoV-2

Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.

A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2

The presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human, and carries the potential for accelerated vaccine development against CoVID-19 for clinical studies.

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

A mouse model in which a SARS-CoV-2 strain was infectious and could cause an inflammatory response and moderate pneumonia is developed, and a panel of adaptive mutations potentially associated with the increased virulence are revealed.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection.

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development…

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection

The susceptibility of a few laboratory rodents to SARS-CoV-2 is evaluated at the Maximum Containment Laboratory, Indian Council of Medical Research National Institute of Virology, Pune, India.

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

It is shown that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic.

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

It is shown that SARS-CoV-2 causes a respiratory disease in rhesus macaques that lasts between 8 and 16 days, which recapitulates the moderate disease that has been observed in the majority of human cases of COVID-19.
...